Carole Gordon, MD
Urology · Oxford, FLNPI 1306888334
Payments from drug & device makers
Across 308 payments — averaging $45.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teleflex LLC$9K
- Axonics, Inc.$1K
- Sumitomo Pharma America, Inc.$689
- Astellas Pharma US Inc$596
- AbbVie$315
- Urovant Sciences Inc$274
- plus $2K from 39 others
What the payments were for
- Consulting fees$8,06657%
- Speaking & faculty fees$3502%
- Food & beverage$5,46839%
- Education$2632%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Solesta$8,066
- Barrigel$350
- INTERSTIM$126
- INLAY$108
- eCoin Device Kit$107
How this compares
$14,147 in reported general payments places this provider in the 75th percentile of 935 urology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 354 | $340,640 |
| MyrbetriqMirabegron | 270 | $290,230 |
| Mirabegron ErMirabegron | 14 | $8,862 |
| Methenamine Hippurate | 87 | $8,769 |
| Tolterodine Tartrate ErTolterodine Tartrate | 45 | $4,921 |
| Tamsulosin Hcl | 312 | $3,931 |
| Oxybutynin Chloride ErOxybutynin Chloride | 122 | $3,381 |
| Estradiol | 19 | $2,177 |
| Solifenacin Succinate | 28 | $2,077 |
| NitrofurantoinNitrofurantoin Macrocrystal | 72 | $1,334 |
| Finasteride | 64 | $1,086 |
| Trospium Chloride | 18 | $951 |
| Ciprofloxacin Hcl | 139 | $877 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 119 | $768 |
| Oxybutynin Chloride | 31 | $525 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $689 | $340,640354 claims |
| Astellas Pharma US IncMyrbetriq | $596 | $290,230270 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 935 urology providers in Florida.
Other urology in Oxford
- Steven KesterPompano Beach$5.7M
- Harvey SamowitzHallandale Beach$3.6M
- Paul PeritoCoral Gables$3.6M
- Graham GreeneLakeland$2.5M
- Scott SellingerTallahassee$2.3M
- Fernando BiancoHialeah$2.2M
- Osvaldo PadronTampa$1.3M
- Mark Anthony GonzalgoMiami$1.1M
- Paul CrispenGainesville$1.1M
- Craig HermanPompano Beach$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.